Sun Pharmaceutical Industries updates on lawsuit filed by Ranbaxy against USFDA

Image
Capital Market
Last Updated : Oct 09 2015 | 1:47 PM IST
Sun Pharmaceutical Industries announced that the Company has withdrawn its appeal in the lawsuit filed by erstwhile Ranbaxy Laboratories (Ranbaxy) in November 2014 in a U.S. District Court against U.S. Food and Drug Administration (FDA). This lawsuit challenged FDA's revocation of Ranbaxy's tentative approvals for its generic versions of Nexium and Valcyte in the US. The Company do not believe that the withdrawal of said lawsuit by Sun Pharma will have any materially adverse financial impact on the Company.

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 09 2015 | 1:16 PM IST

Next Story